Lyell reports Q3 2026 results, new ronde-cel data headed to ASH
Lyell Immunopharma plans to present updated PiNACLE and Phase 1/2 ronde-cel data at ASH 2026, while keeping its mid-2027 pivotal data and BLA timeline intact.
SEC filing
3 stories
Lyell Immunopharma plans to present updated PiNACLE and Phase 1/2 ronde-cel data at ASH 2026, while keeping its mid-2027 pivotal data and BLA timeline intact.
SEC filing
The company agreed to sell over 7.4 million shares at $10.77 apiece to institutional investors, with closing expected November 4, 2026.
SEC filing
Lyell now expects additional clinical data and its End-of-Phase 1 FDA meeting for the colorectal cancer CAR T candidate in 2027, not sooner.
SEC filing